Skip to main content

Table 2 Biochemical parameters for all patients at baseline (week 0), after the first treatment period (week 2), after washout (week 4) and after the second treatment period (week 6)

From: Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial

 

Groupa

Baseline

After the first treatment period

After washout

After the second treatment period

calcium (mmol/l) mean ± SD

1

2.33 ± 0.10

2.34 ± 0.11

2.35 ± 0.08

2.33 ± 0.07

 

2

2.28 ± 0.07

2.30 ± 0.12

2.31 ± 0.11

2.34 ± 0.11

phosphate (mmol/l) mean ± SD

1

1.08 ± 0.24

1.11 ± 0.24

1.16 ± 0.20

1.11 ± 0.19

 

2

1.03 ± 0.21

1.01 ± 0.18

1.04 ± 0.17

1.05 ± 0.19

creatinine (μmol/l) mean ± SD

1

141.1 ± 29.7

143.4 ± 27.1

138.9 ± 29.1

146.6 ± 35.1

 

2

156.9 ± 26.8

166.2 ± 24.7

158.3 ± 21.6

169.5 ± 29.6

eGFR (ml/min/1,73 m2) mean ± SD

1

40.1 ± 7.0

38.9 ± 6.0

40.8 ± 7.7

38.9 ± 7.7

 

2

36.4 ± 5.0

33.8 ± 2.7

35.6 ± 3.3

33.5 ± 6.3

25(OH) vitD (nmol/l) mean ± SD

1

99.4 ± 23.7

94.9 ± 22.3

93.8 ± 26.1

86.1 ± 18.0

 

2

88.0 ± 22.0

86.6 ± 25.6

84.4 ± 31.0

85.6 ± 30.6

FePO4 (%)b mean ± SD

1

26.8 ± 6.7

33.5 ± 9.1

31.7 ± 11.6

29.3 ± 8.6

 

2

34.5 ± 9.5

36.3 ± 10.5

38.1 ± 12.2

41.0 ± 11.7

1.25(OH)2 vitD (pmol/l) median, range

1

72.0 (23.0-112.0)

70.0 (29.0-130.0)

64.0 (32.0-94.0)

61.0 (32.0-108.0)

 

2

65.5 (46.0-175.0)

56.6 (37.0-125.0)

70.0 (27.0-89.0)

60.5 (37.0-99.0)

FGF23 (pg/ml) mean ± SD

1

90.7 ± 28.4

105.8 ± 41.6

102.6 ± 33.1

79.1 ± 36.5

 

2

110.2 ± 73.7

127.6 ± 76.6

142.3 ± 52.2

110.4 ± 41.7

PTH (pg/ml) median, range

1

35.9 (16.3-147.4)

26.5 (14.6-55.2)

35.0 (14.3-72.5)

36.1 (13.4-106.9)

 

2

35.3 (22.6-73.9)

38.7 (21.2-61.0)

33.7 (23.6-63.1)

37.7 (19.7-71.3)

PINP (ÎĽg/l) median, range

1

56.5 (23.2-115.6)

53.0 (24.5-133.8)

52.8 (30.0-89.7)

60.8 (28.3-82.2)

 

2

36.9 (17.1-55.6)

40.5 (20.3-61.4)

37.9 (17.5-55.4)

38.4 (16.8-49.2)

Osteocalcin (ng/ml) median, range

1

17.3 (7.6-37.7)

18.1 (8.9-38.7)

16.5 (9.4-35.6)

18.1 (9.6-34.9)

 

2

12.8 (7.4-25.2)

13.5 (7.7-28.0)

13.6 (9.7-24.5)

13.4 (10.5-26.4)

BALP (U/L) median, range

1

24.3 (14.7-43.4)

22.8 (13.0-37.8)

25.1 (13.0-39.3)

27.1 (13.7-41.2)

 

2

17.9 (12.7-32.0)

19.7 (10.8-33.0)

19.2 (9.4-35.1)

21.3 (11.6-36.6)

NTx (nM BCE)c median, range

1

16.8 (10.3-77.0)

14.4 (10.4-54.8)

13.6 (10.2-25.6)

13.9 (11.1-42.2)

 

2

13.2 (5.9-34.3)

11.9 (7.3-18.3)

11.8 (6.9-21.4)

14.1 (8.0-22.1)

  1. aGroup-1: The alphacalcidol-sevelamer group: alphacalcidol for two weeks (first treatment period) followed by sevelamer carbonate (second treatment period) after two weeks washout (data shown for the nine patients that completed the crossover study).
  2. Group-2: The sevelamer-alphacalcidol group: sevelamer carbonate for two weeks (first treatment period) followed by alphacalcidol (second treatment period) for two weeks after two weeks washout.
  3. bThe treatment difference was statistically significant (p = 0.028).
  4. cnM BCE = nmol Bone Collagen Equivalents.
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us